26th Annual National Conference Oct 3
TUESDAY, OCTOBER 3, 2017 — Attending the full daily program will earn 5.5 contact hours (.55 CEUs). ACPE UAN 0860-0000-17-026-L01-P/0860-0000-17-026-L01-T
Have We Achieved Pareto Optimality or Pareto Efficiency in Transplantation? Michael Abecassis, MD, MBA, Northwestern University
Pareto optimality is a formally defined concept used to judge the efficiency of a distribution when shared goods or resources are allocated to many. Pareto efficiency occurs when all resources are exhausted, and any change in allocation will make at least one party worse off. During this session, Dr. Abecassis will discuss similarities and differences between Pareto optimality, equity, and social optimality in order to provide a conceptual framework to better understand the dynamics and behaviors we are currently witnessing in national debates around liver allocation.
The Fight Against the Prescription Opioid Abuse Epidemic, William B. Leasure, MD, Mayo Clinic
Opioid abuse is a serious public health issue. Drug overdose is a leading cause of injury death in the United States, and there is a clear correlation between opioid-prescribing rates and overdose death rates. This fact accentuates the importance of prescribing guidelines that encourage the use of opioids only when benefits outweigh risks and that promote safe use when opioids are needed. This session will discuss opioid-prescribing guidelines for chronic pain; the clinical decision-making process to reduce inappropriate opioid prescribing; and how organ donations have increased in the wake of the opioid epidemic.
Cardiovascular Disease: Guidelines and Challenges in Patient Management, Haitham Ahmed, MD, MPH, Cleveland Clinic
In 2013, the American College of Cardiology (ACC) and the American Heart Association (AHA), developed new guidelines for the treatment of blood cholesterol and risk assessment of atherosclerotic cardiovascular disease (ASCVD). The new guidelines recommend the use of statin therapy as the medication of choice in ASCVD risk reduction. This was a major shift from the old approach, creating controversies and a state of confusion. As a result of these new guidelines, health care providers require additional information about how to prevent, treat and manage risk factors for cardiovascular disease. This session will provide insight into the application of these new guidelines to current cardiovascular practices, identify challenges and barriers faced by health care providers, and demonstrate the importance of an interdisciplinary team in the care of patients with cardiovascular disease.
Chronic Kidney Disease (CKD) Continuum: The Relationship Between Obesity, Diabetes, Cardiovascular Disease and Transplant, Jane C. Tan, MD, Stanford University Medical Center
CKD is associated with an increased risk for cardiovascular disease, progression to end-stage-renal disease (ESRD) and potentially the need for a kidney transplant. This session will explore the relationship between obesity, diabetes, kidney disease, cardiovascular disease and transplant; the challenges of meeting evidence-based guidelines for managing CKD; and the benefits of addressing multiple risk factors simultaneously and the impact on outcomes.
Diabetes: Improvements in Prevention and Care, Ruchi Mathur, MD, FRCP(C), Cedars-Sinai Medical Center
In the United States, an estimated 86 million people are living with prediabetes and 29 million are living with diabetes. Lifestyle management is a fundamental aspect of diabetes care. There is strong and consistent evidence that obesity management can delay the progression of diabetes, and screening and interventions can limit organ damage. Therefore, diabetes patients require initial and ongoing evaluation for diabetes and its related complications. This session will review medical management approaches consistent with guidelines from the American Diabetes Association (ADA) for health maintenance in patients with diabetes and identify barriers for screening patients at increased risk for diabetes. The importance of an interdisciplinary team approach will also be discussed.
Sickle Cell Disease (SCD): Panel Discussion, Lakshmanan Krishnamurti, MD,Children’s Healthcare of Atlanta/Emory University, and Ines Lukombo, Transplant Recipient
SCD is the most common inherited hemoglobin disorder, affecting 70,000–100,000 people in the U.S. Allogeneic hematopoietic stem cell transplant (HSCT) is currently the only curative treatment for severe SCD that offers excellent long-term survival, but access is limited for several reasons, including donor availability, as well as sociocultural and economic barriers. For our last session of the day, an HSCT recipient will share her experience undergoing transplant for SCD and a renowned hematologist will provide an overview of SCD and review evidence-based guidelines for referral and shared decision making. Treatment options including standard of care and curative therapies, and their outcomes will be addressed.
- 5.50 ACPE - Pharmacist
- 5.50 ACPE - Pharmacy Technician